These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16361000)

  • 1. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.
    Tonkin A; Barter P; Best J; Boyden A; Furler J; Hossack K; Sullivan D; Thompson P; Vale M; Cooper C; Robinson M; Clune E; ;
    Heart Lung Circ; 2005 Dec; 14(4):275-91. PubMed ID: 16361000
    [No Abstract]   [Full Text] [Related]  

  • 2. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dyslipidemia in renal disease and transplantation.
    Zolezzi M
    Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
    Stewart RA; North FM; Sharples KJ; Simes RJ; Tonkin AM; White HD;
    N Z Med J; 2008 Feb; 121(1269):11-23. PubMed ID: 18278078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering therapy for adults with diabetes.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Government cholesterol recommendations questioned.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Oct; 15(20):9-10, 12. PubMed ID: 15505935
    [No Abstract]   [Full Text] [Related]  

  • 7. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular health in New Zealand: areas of concern and targets for improvement in 2008 and beyond.
    Ellis CJ; Hamer AW
    N Z Med J; 2008 Feb; 121(1269):5-10. PubMed ID: 18278077
    [No Abstract]   [Full Text] [Related]  

  • 9. Towards consistency between guidelines and policy: lipid management--2005.
    Tonkin AM
    Heart Lung Circ; 2005 Dec; 14(4):237-8. PubMed ID: 16360991
    [No Abstract]   [Full Text] [Related]  

  • 10. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk.
    Schilling C; Knight J; Mortimer D; Petrie D; Clarke P; Chalmers J; Kerr A; Jackson R
    Health Policy; 2017 Dec; 121(12):1233-1239. PubMed ID: 29042060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic syndrome: definition, diagnosis and management.
    Novo S; Balbarini A; Belch JJ; Bonura F; Clement DL; Diamantopoulos E; Fareed J; Norgren L; Poredos P; Rotzocil K; ; ;
    Int Angiol; 2008 Jun; 27(3):220-31. PubMed ID: 18506125
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
    Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL
    J Am Coll Cardiol; 2008 Apr; 51(15):1512-24. PubMed ID: 18402913
    [No Abstract]   [Full Text] [Related]  

  • 15. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.
    Williams B; Poulter NR; Brown MJ; Davis M; McInnes GT; Potter JF; Sever PS; Thom SM;
    BMJ; 2004 Mar; 328(7440):634-40. PubMed ID: 15016698
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factor management: antiatherogenic therapies.
    Gielen S; Sandri M; Schuler G; Teupser D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S29-36. PubMed ID: 19675434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questioning the benefits of statins.
    Mazowita G
    CMAJ; 2005 Nov; 173(10):1210; author reply 1210. PubMed ID: 16275979
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent claudication: a plea for guidelines for medical management.
    Powell JT
    Eur J Vasc Endovasc Surg; 2007 Apr; 33(4):451-2. PubMed ID: 17196850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.